此次爆發由罕見的Bundibugyo病毒株引起，主要透過接觸受感染者的血液和體液傳播。由於當地武裝衝突、大規模人口流離失所，以及脆弱的醫療基礎設施，世界衛生組織等醫療機構的防疫工作受到嚴重阻礙。
儘管目前尚未有可立即使用的疫苗，但針對Bundibugyo病毒株的首批兩種疫苗（由Moderna和牛津大學開發）已開始進行第一期人體安全試驗。專家表示，未來若能成功部署有效疫苗，將能大幅改變應對疫情的動態與成效。（關鍵數字：1）
The Democratic Republic of Congo is experiencing its deadliest Ebola outbreak in history, with the death toll reaching 2,325. The World Health Organization has warned of an intense transmission phase, noting that the actual number of infections could be up to five times higher than the officially reported 4,945 cases.
This outbreak is driven by the rare Bundibugyo strain of the Ebola virus, transmitted through direct contact with infected bodily fluids. Containment efforts by global health agencies are being severely hindered by ongoing armed conflicts, significant population displacement, and the country's fragile healthcare system.
Although no vaccines are available for immediate deployment, the first two vaccines specifically targeting the Bundibugyo strain, developed by Moderna and the University of Oxford, have entered phase 1 human trials. Experts emphasize that the eventual rollout of an effective vaccine will be crucial in changing the trajectory of the response.